Position in EXEL
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$1,447,469
-$193,202 QoQ
Shares Held
26,603
-30.5% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#300
of 751 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Focus Partners Advisor Solutions, LLC holds $11,279,306 across 23 Biotechnology names. EXEL ranks #2 (12.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
28,722 | $3,255,925 | |
| 2 | EXEL |
Exelixis, Inc.
This page
|
26,603 | $1,447,469 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,165 | $1,349,964 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,708 | $848,414 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
10,899 | $623,640 | |
| 6 | CORT |
Corcept Therapeutics Inc
|
6,677 | $580,565 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
1,599 | $385,311 | |
| 8 | TGTX |
Tg Therapeutics, Inc.
|
6,261 | $343,979 |
All Filings in EXEL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,447,469 | 26,603 | Shares | Other | 2026-08-06 | |
| 2026-03-31 | $1,640,671 | 38,253 | Shares | Other | 2026-05-13 | |
| 2025-12-31 | $2,046,291 | 46,687 | Shares | Other | 2026-02-11 | |
| 2025-09-30 | $1,574,810 | 38,131 | Shares | Other | 2025-11-12 | |
| 2025-06-30 | $1,304,415 | 29,592 | Shares | Other | 2025-07-31 | |
| 2025-03-31 | $709,122 | 19,207 | Shares | Other | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||